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Endovascular treatment of thoracoabdominal
aortic aneurysms
Matthieu Guillou, MD,a Aurelia Bianchini, MD,a Jonathan Sobocinski, MD,a Blandine Maurel, MD,a
Piervito D’elia, MD,a Mark Tyrrell, MD,b Richard Azzaoui, MD,a and Stéphan Haulon, MD, PhD,a Lille,
France; and London, United Kingdom
Background: Development in endograft design has extended endovascular treatment to include thoracoabdominal aortic
aneurysms (TAAA). We report our experience using fenestrated and branched endografts in the management of TAAA.
Methods: We analyzed a cohort of consecutive patients treated electively for TAAA using endovascular techniques between
2006 and 2011. All data were collected prospectively. The relationships between preoperative risk factors and clinical
outcome were examined using univariate and multivariate statistical techniques. We also compared the outcomes between
33 previously published early cases (EC) with the last 56 later cases (LC).
Results: Eighty-nine patients (83 men) were treated. Median age was 69 years. All patients were deemed unfit for open
surgery. The 30-day and in-hospital mortality rates were 8.9% and 10%, respectively. Multivariate analysis showed
in-hospital mortality was associated with preoperative chronic renal failure and advanced age. Higher postoperative mean
arterial blood pressure was a protective factor. Technical success rate was 96.6% (94% and 98% in the EC and LC groups,
respectively; P  .14). The spinal cord ischemia (SCI) rate was 7.8% (15% and 3% in the EC and LC groups, respectively;
P  .063) and was associated with chronic obstructive pulmonary disease and procedure duration. Six patients (6.7%)
required temporary filtration, but none required permanent renal support (associated with left ventricular ejection
fraction<40% and procedure duration). Median procedure duration decreased from 232 to 203 minutes (P .01) in the
EC and LC groups, respectively. Actuarial survival was 86.8%  3.7% at 1 year and 74.7%  6% at 2 years.
Conclusions: Although we have treated a cohort at high operative risk, our midterm results compare favorably with the
published series of conventional surgery. Accurate hemodynamic control represented by high-normal perioperative blood
pressure seems to protect against severe postoperative complications. ( J Vasc Surg 2012;56:65-73.)
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oThoracoabdominal aortic aneurysm (TAAA) repair
continues to represent a clinical and technical challenge.
Conventional open repair still carries appreciable morbidity
and mortality rates, even in high-volume, experienced cen-
ters.1 Modern series report perioperative mortality rates
ranging from 4% to 16% and in-hospital mortality ap-
proaching 20%.2 Despite improvement in perioperative
care and various surgical adjuncts, cardiopulmonary, renal,
and neurologic complications, such as spinal cord ischemia
(SCI), are still common problems after open repair.3
The endovascular treatment of infrarenal aortic aneu-
rysms has gained widespread acceptance and has revolu-
tionized the field of vascular surgery during the last decade.
More recently, ingenious technical and material develop-
ments in endovascular technology have enabled the manu-
facture of custom-made endografts to treat even more
challenging cases. These devices allow the treatment of
aneurysmal segments of the TAAA, while preserving blood
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http://dx.doi.org/10.1016/j.jvs.2012.01.008ow to visceral arteries through fenestrations, branches, or
combination of the two.
Although there is still a lot to be learned about these
ew techniques, encouraging results in feasibility and safety
ave been reported.4-7 Nevertheless, patients undergoing
hese procedures, most of whom have been refused open
urgery, remain vulnerable postoperatively and are particu-
arly at risk of SCI and acute renal failure. In 2010, we
ublished our initial experience of 33 patients.4 Here we
escribe our single-institution experience with the endo-
ascular treatment of 89 consecutive patients presenting
ith complex TAAA disease.
ETHODS
Patients. Until 2006, 15 to 20 open TAAA repairs
ere performed each year at our institution. The number of
early open repairs has now dropped to 10, but the
verall number of TAAA repairs (open endovascular) has
ncreased because many high-risk patients are now referred
o our center specifically for an endovascular repair. The
ndications for treatment have not changed: maximal aortic
iameter 55 mm or rapid growth, defined as 5 mm in
he last 6 months.
All data regarding the use of custom-made branched
nd fenestrated endografts for TAAA are collected prospec-
ively. Between August 2006 and July 2011, we treated 89
onsecutive patients at our institution. Written informed
onsent was obtained from all patients. All aneurysms but
ne were considered degenerative. The exception was a
8-year-old patient diagnosed with Bruton agammaglobu-
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July 201266 Guillou et allinemia, an X-linked recessive disorder associated with re-
current bacterial infections. This patient was thus consid-
ered at high risk and had a contraindication for open
surgery because of this high risk of infection. No connective
tissue disorders are associated with Bruton agammaglobu-
linemia, and we considered it very unlikely that this patient
had a degenerative aneurysm.
The median age was 69 years (range, 38-88 years), and
93% were men. All patients were deemed to be at physio-
logic high risk for open surgical repair (Table I). The
high-risk criteria for open abdominal aortic aneurysm repair
have been determined by the Agence Française de Sécurité
Sanitaire des Produits de Santé (http://afssaps.sante.fr/
index.htm), the counterpart in France of theU.S. Food and
Drug Administration, and are reported in Table II.8
According to the reporting standards for thoracic en-
dovascular aortic repair (TEVAR),9 the anatomic distribu-
tion of the aneurysms that were treated were 4 Crawford
type I, 15 type II, 25 type III, and 45 type 4 TAAA.
Preoperative considerations. The preoperative work
up included a complete physical examination, cardiac
evaluation with stress cardiac echography and coronary
angiography where indicated, respiratory function tests,
and routine blood tests. Renal function was optimized
preoperatively with hydration and administration of N-
acetyl cysteine according to our standard protocol. Preop-
erative chronic renal insufficiency was defined as an esti-
mated glomerular filtration rate (eGFR) value of 60
mL/min/1.73 m2 as recommended by the National Kid-
ney Foundation.10 A decrease in eGFR of 30% or more
measured on postoperative day 7 was considered clinically
significant.11
The fenestrated/branched endografts were designed
Table I. Patient characteristics
No. (%) or
Variables
median  SD
(range)
Age, years 69.4  8.99 (38-88)
Male sex 83 (93)
ASA 3 81 (91)
Maximal aortic diameter, mm 61  11.057 (50-100)
CAD/CABG/stenting 28 (39)
High blood pressure 72 (80)
Dyslipidemia 56 (65)
GFR 60 mL/min (Cockcroft) 24 (27)
Smoking, active and history 71 (79)
History of abdominal aorta surgery 27 (30)
Diabetes mellitus 16 (18)
LVEF 40% 6 (6.7)
COPD 17 (19.1)
Antiplatelet therapy 59 (66)
-blocker therapy 36 (40.4)
Statin therapy 52 (58.4)
ACE inhibitors 52 (58.4)
ACE, Angiotensin conversion enzyme; ASA, American Society of Anesthe-
siologists; CABG, coronary artery bypass graft; CAD, coronary artery dis-
ease; COPD, chronic obstructive pulmonary disease; GFR, glomerular fil-
tration rate; LVEF, left ventricular ejection fraction; SD, standard deviation.after careful analysis of fine-cut contrast-enhanced com- tuted tomography (CT) scans of the chest, abdomen, and
elvis on a workstation to allow three-dimensional manip-
lation (Aquarius WS; Terarecon Inc, Mateo, Calif). All
ndografts had 3 or 4 branches or fenestrations, or both, to
ccommodate visceral vessels. We planned minimal aortic
nd iliac sealing zones of 20 mm in length over healthy
roximal and distal segments. A detailed description of
AAA endograft design and implantation technique has
een previously reported.4
Implantation. Procedures were performed under
eneral anesthesia with invasive monitoring. Spinal drain-
ge was used for Crawford type I, II, or III TAAA and in
atients being treated for type IV aneurysms who have had
revious abdominal aortic surgery. The endovascular de-
ices consisted of a multibranched or fenestrated main
omponent with proximal thoracic and distal abdominal
ortoiliac extensions as required.
For fenestrated endografts, the proximal fenestrated
omponent of the graft is advanced into the visceral aorta,
nd fenestrations are oriented to match the origins of the
isceral target vessels using radiopaque gold markers and
uoroscopy. The graft is then slowly deployed, without re-
easing the proximal stent and posterior diameter-reducing
ires. A 20F sheath is inserted through the contralateral
emoral artery and positioned with its distal end at the aortic
ifurcation. Various wire/catheter combinations are used to
atheterize the fenestrations and visceral arteries. The hydro-
hilicwires are exchanged for stiff wires, and a 55-cm-long, 7F
heath is positioned in each visceral artery through multiple
unctures of the 20F sheath’s valve.
Bridging balloon-expandable covered stents are then
dvanced inside the 7F sheaths but are left undeployed to
nchor and stabilize the entire endovascular system. The
roximal stent of the fenestration/branch-bearing compo-
ent is then deployed, and the diameter reducing ties are
eleased. The visceral bridging stents are expanded so that 4
o 5 mm of each protrudes into the aortic lumen. Finally,
able II. Agence Française de Sécurité Sanitaire des
roduits de Santé (AFSSAPS) high-risk criteria
. Age 80 years
. Coronary artery disease evidenced by a history of
myocardial infarction or angina with a positive
function test and coronary artery lesions that
cannot be revascularized
. Symptomatic heart failure
. Inoperable tight aortic narrowing
. Left ventricular ejection fraction 40% of predicted
. COPD evidenced by FEV11.2 L/s; vital capacity
50% of the predicted value as a function of age,
sex, and weight; PaCO2 45 mm Hg or PaO2
60 mm Hg; or home oxygen therapy
. Renal failure corresponding to serum creatinine
200 mol/L before contrast medium injection
. Hostile abdomen owing to the presence of ascites
or other signs of portal hypertension
OPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory
olume in 1 second.he protruding segments are flared by overdilatation using a
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Volume 56, Number 1 Guillou et al 6712/20-mm balloon to obtain a seal around the fenestra-
tions of the device.
In case of a device with branches, the branch-bearing
component is positioned so that the distal ends of the
branches lie 10 to 15 mm above the ostia of the target
vessels. If the device has branches but not fenestrations, the
distal body and iliac extensions are deployed once the
branched component is in position, the large femoral
sheathes are removed, and the arteriotomies are closed
(over small sheathes if necessary) to allow for the early
restoration of blood flow to the pelvis and lower limbs. In
devices that incorporate a combination of branches and
fenestrations, the fenestrations are completed as the first
priority using the techniques described above and the large
femoral sheaths are removed before the branches are com-
pleted.
Through axillary arterial access, an 80-cm-long 10F
sheath is advanced into the endograft, and each branch and
its corresponding artery is catheterized, wired, and stented
with a self-expanding covered bridging stent. This se-
quence is completed one branch at a time, usually starting
with the most distal branch first. The stents are each de-
ployed over a stiff wire, and a bare nitinol self-expandable
stent is added inside each covered stent to add stability and
avoid kinks.
If the proximal sealing zone involves the occlusion of
the left subclavian artery origin, a debranching left carotid-
to-subclavian bypass is performed.
As defined by Fillinger et al,9 technical success is char-
acterized by the successful introduction and deployment of
the device in the absence of surgical conversion to open
repair. Failure is defined as death 24 hours of surgery,
occlusion of target vessels, type I or III endoleaks, or graft
occlusion.
Postoperative management and follow-up. Patients
spent a minimum of 24 hours in the intensive care unit for
active physiologic monitoring. We maintained a mean ar-
terial pressure (MAP) 90 mm Hg and a central venous
pressure 15 mm Hg to improve spinal cord perfusion
during the first 72 hours postoperatively. In patients with-
out neurologic symptoms, cerebrospinal fluid (CSF) pres-
sure was maintained at 10 mmHg during the first 48 hours
and removed at 72 hours. In patients with neurologic
symptoms, we reduced CSF pressure to 5 mm Hg and
optimized the hemodynamic and physiologic status. We
use activated clotting time routinely to assess coagulopathy
during and after this procedure. Plasma, platelets, and red
packed cells transfusions were used as needed.
All patients underwent 64-slice CT angiography (CTA)
before discharge from the hospital. Follow-up clinical as-
sessment, laboratory testing (including GFR evaluation),
CTA, duplex ultrasound imaging, and plain chest and
abdominal radiographs were obtained at 1, 6, 12, 18, and
24 months, and yearly thereafter. In patients with renal
dysfunction, postoperative CT scans were without contrast
and contrast ultrasound imaging was also performed.We compared the results from our previously published
eries of 33 early cases (EC) with results from our last 56
ases (LC).
Statistical analysis. Statistical analysis was performed
ith SPSS 17.0 software (SPSS Inc, Chicago, Ill). Variables
ere compared between the two groups using the two-
ided Fisher exact test for discrete data and the Student
-test for continuous data. Multivariate predictors of SCI,
umulatedmorbidity andmortality rates, and postoperative
ialysis were evaluated using logistic regression models,
ncluding all variables that were significant on univariate
nalysis (P .05). Actuarial survival analysis was performed
sing Kaplan-Meier life tables. Association of risks factors
ith in-hospital mortality was determined by Cox regres-
ion. For each variable, log-linearity tests and proportional
azards models were performed. P values of .05 were
onsidered statistically significant.
ESULTS
During the 5-year study period, 89 patients with TAAA
nderwent treatment with custom-designed fenestrated/
ranched endografts (Fig 1).
Devices. The total number of fenestrations was 192,
ncluding 123 renal, 54 superior mesenteric artery (SMA),
nd 15 celiac trunk fenestrations. The total number of
ranches was 102, comprising 40 renal, 33 SMA, and 29
eliac trunk. Purely fenestrated stent grafts (3 or 4 fenestra-
ions) were designed in 48 patients, and stent grafts with
ranches only in 24 patients. The remaining 17 patients
ere treated with grafts combining branches and fenestra-
ions (Fig 2).
Procedure. The technical success rate was 96.6% (oc-
lusion of a target vessel in three patients). Aortic stent
rafts were fully deployed in all patients, and 287 of the 292
arget vessels (98%) were revascularized using covered
tents. Where failure to cannulate the target visceral vessel
ccurred, the relevant device branch was occluded with an
ndovascular occlusion device, and the need for open re-
ascularization was evaluated on an individual basis:
● Failure to catheterize a left renal artery in one patient
was managed by means of an extra-anatomic bypass
Fig 1. Number of patients treated per year.graft. This target vessel thus remained patent.
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July 201268 Guillou et al● Failure to catheterize a renal artery and the celiac trunk
occurred in one patient. An extra-anatomic bypass was
not performed because of his physiologic status.
● One celiac trunk fenestration and one celiac trunk
branch occlusion were diagnosed on completion an-
giogram. In both cases, an arcuate ligament was dem-
onstrated on the preoperative CT scan.
Comparison of EC and LC. The groups did not
differ in median age, distribution of American Society of
Anesthesiology classification (ASA), or Crawford aneurysm
extent. The technical success was 94% in EC and 98% in LC
(P .14). For the group as a whole, the median procedure
time was 220.5 minutes (range, 120-490 min) and was
significantly decreased from 232 minutes in EC to 203
minutes in LC (P  .01). The median contrast volume
injected per procedure was 182 mL (range, 20-460 mL),
and the median fluoroscopy dose was 12.7 mBq/m2
(range, 2.4-29.7 mBq/m2).
Mortality. The 30-day mortality rate was 8.9% (8
patients), 6% in EC and 10.7% in LC (P  .092). The
in-hospital mortality was 10% (9 patients). There were no
intraoperative deaths.
Multiple organ failure developed in six patients at days
4, 7, 12, 18, 29, and 42. The underlying causes were (1)
massive cholesterol embolism syndrome, (2) acute ischemic
pancreatitis after postoperative thrombosis of the celiac
branch of the device, (3) postoperative coagulopathy and
pulmonary sepsis, (4) massive cholesterol emboli and pul-
monary sepsis, (5) hemorrhage after intraoperative rupture
of an external iliac artery treated with an iliofemoral bypass
graft, and (6) acute renal failure and severe pulmonary
Fig 2. A three-dimensional reconstruction shows a thoracoab-
dominal endograft comprising three branches for the superior
mesenteric artery, celiac trunk, right renal, and a fenestration for
the left renal artery.sepsis. IThere were three cardiac-related deaths: one patient
ied of Takotsubo syndrome (stress cardiomyopathy), an
8-year-old patient with a preoperative history of coronary
rtery disease and renal failure requiring dialysis developed
evere coagulopathy and cardiac failure and died 30 hours
fter the procedure, and one patient sustained an acute
yocardial infarction at day 3 and died despite attempted
alvage coronary angioplasty.
Univariate analysis revealed that advanced age, maxi-
al aneurysm diameter, and preoperative chronic renal
ailure were associated with in-hospital death (Table III).
igh postoperative MAP was a protective factor. Multivar-
ate analysis confirmed chronic renal failure, advanced age,
nd higher postoperative MAP were significant and inde-
endent (Table IV). The risk of in-hospital death doubled
ith every 6 years of increasing age.
Morbidity. The median lengths of intensive care unit
nd hospital stays were 2.1 (range, 0-17 days) and 13 days
range, 8-42 days), respectively.
Seven (7.8%) cardiac events occurred postoperatively.
ive (5.6%) episodes of cardiac failure recovered after treat-
ent, and two (2.2%) postoperative myocardial infarctions
ere managed medically. One patient had a cerebrovascu-
ar accident with right arm paresis that improved with
ehabilitation.
SCI developed in seven patients (7.8%). There was no
ncidence of SCI in patients with type IV TAAA. One
atient with SCI died on postoperative day 7; two devel-
ped complete, permanent paraplegia; and four are able to
alk after rehabilitation. SCI was diagnosed immediately
ostprocedure in three patients and 24 hours postproce-
ure in the other four.
Chronic obstructive pulmonary disease (COPD) and
rocedure duration were the only risk factors associated
ith SCI in univariate analysis (Table III). Multivariate
nalysis confirmed that procedure duration (P  .01) and
OPD (P  .044) were independent factors predictive of
CI (Table IV).
Ten patients (11%) were diagnosed with a decrease
f 30% of postoperative eGFR, and six (6.7%) required
emporary filtration but none required permanent renal
upport. Two patients who required hemofiltration had
reoperative chronic renal failure.
Univariate analysis identified preoperative left ventric-
lar ejection fraction 40% and procedure duration as
redictors of the requirement for postoperative dialysis
Table III). On multivariate analysis, multiple logistic re-
ression analysis confirmed both of these as significant
ndependent risks factors for postoperative dialysis (P 
009 and P  .019, respectively; Table IV).
The cumulative early mortality and SCI rate was 15.7%
14 patients). Univariate analysis found advanced age,
OPD, procedure time, and Crawford extent I, II, and III
neurysms were risks factors associated with a higher cumu-
ative early mortality and SCI rate (Table V). Preoperative
-blockade and statin use were independently protective.
ultiple logistic regression confirmed Crawford extent I,I, and III TAAA (compared with type IV) and long
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Volume 56, Number 1 Guillou et al 69procedure times as significant independent risk factors for a
poor outcome (Table VI). Preoperative -blockade was
confirmed as a protective factor. Log linearity testing dem-
onstrated that the cumulative early mortality and SCI risk
was multiplied by 2.3 for every operative hour, whereas the
SCI risk alone was multiplied by a factor of 2.6.
During early follow-up, seven patients required addi-
tional surgical procedures. Three patients underwent drain-
age for groin hematomas. Four patients suffered from acute
or subacute unilateral lower limb ischemia: one required a
Table III. Univariate analyses of factors associated with in
postoperative dialysis after thoracoabdominal aortic aneury
In-hospital mortal
Variables RR
Male sex 0.316 .1
Chronic renal failure 4.733 .0
History of abdominal aortic surgery 1.457 .6
Advanced age (per year) 1.182 .0
High blood pressurea 1.595 .6
Smoking 1.648 .4
Diabetes mellitus 0.844 .8
CAD/CABG/stenting 1.457 .6
LVEF 40% 0.690 .7
Antiplatelet therapy 0.44 .2
-blocker therapy 0.229 .1
ACE inhibitor therapy 1.648 .5
Statin therapy 0.767 .6
COPD 3.752 .5
Procedure duration (per min) 1.002 .5
Maximal aortic diameter (per mm) 1.083 .0
Mean arterial pressure
Per operative (per mm Hg) 1.005 .8
Postoperativea (per mm Hg) 0.909 .0
Aneurysm types I, II, III vs IV 5.86 .9
Postoperative dialysis 4.99 .0
Spinal chord ischemia 1.054 .9
ACE, Angiotensin conversion enzyme; ASA, American Society of Anesth
COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejecti
aFactor associated with decreased risk.
Table IV. Multivariate analyses for in-hospital mortality,
paraplegia, and postoperative dialysis
Variables OR/RR (95% CI) P
In-hospital mortality
Chronic renal failure 21.3 (2.589-175) .004
Post-op MAP (per mm Hg)a 0.782 (0.663-0.923) .004
Age (per year) 1.116 (1.004-1.240) .042
Spinal chord ischemia
COPD 8.5 (1.063-69.3) .044
Procedure duration (per min) 1.016 (1.004-1.029) .010
Post-op dialysis
LVEF 40% 40.6 (2.477-668) .009
Procedure duration (per min) 1.015 (1.002-1.028) .019
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; OR,
odds ratio; RR, relative risk.
aFactor associated with a decreased risk.femoral catheter thromboembolectomy, the second under- aent percutaneous iliac angioplasty and stenting of a severe
liac stenosis distal to the iliac limb, the third required a
emoral endarterectomy of an obstructing atherosclerotic
laque at the femoral puncture site, and the fourth had a
emoral-to-profunda bypass.
Postoperative CT imaging revealed endoleaks in 19
f 89 patients (21%). Type II endoleaks were the most
ommon (17 patients), followed by type III (2 patients).
ostoperative CT imaging did not readily distinguish
etween types III and II endoleaks in these two patients.
n addition, these type III endoleaks had not been
isualized on the completion angiogram performed at
he end of the procedures. In one, the type III endoleak
as not identified on the 6-month follow-up CTA. The
ther patient could not have contrast injection because
f chronic renal insufficiency, but his aneurysm diameter
emained stable over time. No type I or IV endoleaks
ere identified.
Follow-up. No patients were lost to follow-up. The
edian follow-up time was 17 months (range, 1-48
onths). Nine patients died during follow-up, none as a
onsequence of aneurysm rupture (myocardial infarction
n four, stroke in two, respiratory distress in one, and
ithdrawal of care in an 83-year-old bedridden patient).
he 1-year mortality rate was 14.6% (13 of 89). Actuarial
urvival was 86.8%  3.7% at 1 year and 74.7%  6% at 2
ears (Fig 3).
Late endoleaks occurred in three patients at 12, 12,
pital mortality, spinal chord ischemia (SCI), or
TAAA) endovascular repair
SCI Postoperative dialysis
OR P OR P
0.461 .505 0.405 .442
1.354 .725 1.857 .409
1.114 .88 2.667 .221
1.005 .896 1.118 .077
0.219 .067 1.09 .99
2.759 .185 1.190 .83
10-9 .95 0.726 .077
0.171 .107 1.008 .99
10-9 .99 12.3 .016
1.302 .757 1.127 .69
10-9 .99 0.461 .375
1.957 .43 0.812 .794
0.331 .15 0.406 .261
6.6 .021 3.577 .121
1.016 .003 1.009 .05
1.019 .538 1.054 .065
0.99 .126 0.99 .614
1.011 .849 1.008 .88
108 .99 5.921 .085
2.028 .542
ists; CABG, coronary artery bypass graft; CAD, coronary artery disease;
tion; OR, odds ratio; RR, relative risk; SCI, spinal chord ischemia.-hos
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July 201270 Guillou et alII). The late type III endoleak, the only one that re-
quired treatment, was managed by the placement of an
additional SMA stent 8 months after TAAA repair and
exclusion of a hypogastric aneurysm using a limb exten-
sion and coil occlusion of the internal iliac a further 15
months after the initial procedure.
At 15 months after the TEVAR repair, one patient
had an ascending aortic and arch repair associated with
debranching of the supra aortic trunks and a thoracic
endograft for an aneurysmal enlargement proximal to a
previous open thoracic aneurysm repair. At 27 months
after TAAA treatment, one patient needed a crossover
bypass for a limb occlusion, and a kinked left renal artery
stent in another patient was treated with an additional
renal stent. Finally, one patient required a distal bifur-
cated endograft 50 months after the TAAA repair for
Table V. Univariate analyses of factors associated with
cumulated early mortality and SCI after thoracoabdominal
aortic aneurysm (TAAA) endovascular repair
Variables OR P
Male gender 0.239 .239
Chronic renal failure 2.650 .125
History of abdominal aortic
surgery
1.5 .494
Advanced age (per year) 1.105 .012
High blood pressure 0.410 .192
Smoking 2.3 .159
Diabetes mellitus 0.313 .282
CAD/CABG/stenting 0.314 .095
LVEF 40% 10-9 .99
Antiplatelet therapy 0.720 .595
-blocker therapya 0.088 .024
ACE inhibitor therapy 1.67 .425
Statin therapya 0.272 .034
COPD 6.1 .004
Procedure duration (per min) 1.015 .001
Mean arterial pressure
Preoperative (per mm Hg) 0.99 .729
Postoperativea (per mm Hg) 0.221 .221
Aneurysm types I, II, III vs IV 19.5 .005
ACE, Angiotensin conversion enzyme; ASA, American Society of Anesthe-
siologists; CABG, coronary artery bypass graft; CAD, coronary artery dis-
ease; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular
ejection fraction; OR, odds ratio.
aFactor associated with a decreased risk.
Table VI. Multivariate analyses of factors associated with
cumulated early mortality and spinal chord ischemia after
thoracoabdominal aortic aneurysm (TAAA) endovascular
repair
Variable OR (95% CI) P
-blocker therapya 0.033 (0.002-0.437) .010
Procedure duration (per min) 1.014 (1.002-0.437) .010
Aneurysm types I, II, III vs
IV
13.754 (1.371-137) .026
CI, Confidence interval; OR, odds ratio.
aFactor associated with a decreased risk.exclusion of a common iliac artery aneurysm. The actu- wrial freedom from reintervention was 95.8%  3% at 2
ears (Fig 4).
ISCUSSION
Endovascular therapists are attempting to extend the
enefits of a total endovascular approach to patients with
natomically challenging aortic aneurysms, including those
hat involve the visceral vessels. The hybrid technique (con-
isting of an open laparotomy and debranching of all of the
isceral vessels with reperfusion from a remote inflow site,
ollowed by exclusion of the aneurysm using a tube en-
ograft) has also been advocated as a less invasive option.
onetheless, this technique carries a high risk of morbidity
nd mortality.12 In our experience, this approach showed
imilar results to the conventional open TAAA approach.
onsequently we have committed our program to develop
he expertise necessary to treat TAAA using a totally endo-
ascular approach.
The morbidity and mortality reported in this series is
isappointing for a technique billed as minimally invasive.
owever, it should be borne in mind that all of the patients
ncluded in the present study were considered high risk and
eemed unfit for open surgery. Furthermore, these results
nclude our learning curve (we have here described our
nedited, total experience of this technique), which in-
ludes revision of protocols regarding patient selection as
ell as operative technique and perioperative management.
hen we started using these complex devices, we initially
xtended the option of endovascular treatment to exces-
ively fragile patients (combination of chronic renal failure,
dvanced age, and COPD) who we would now exclude
rom treatment.
Most of the postoperative cardiac and pulmonary
vents (acute pulmonary edema and pneumonias) have
een successfully managed. We report a 30-day mortality
ate of 8.9% and a 1-year actuarial survival rate of 86.8%
Fig 3), which is consistent with our preliminary results4
nd also with the largest published series, which reports
0-day mortality rates of 5.5% to 9.1%, with 1-year survival
ates of 76% to 81%.7,13 We are not surprised to find that
atients with Crawford extent I, II, or III aneurysms had a
igher risk of postoperative SCI and death compared with
ype IV (odds ratio, 13.7; P  .02). In our experience,
owever, patients with types I, II, and III aneurysms had
imilar outcomes when compared with each other.
Procedure time also influenced outcome. Long proce-
ures were independently associated with postoperative
CI and renal dialysis as well as with a greater chance of
umulative SCI and in-hospital death. In this group of 89
atients, the addition of 60 minutes to the procedure more
han doubled the risk of SCI or dialysis. Preoperative
-blocker treatment had a protective influence on the cu-
ulative early mortality and SCI rate.
We observed an “on-off” phenomenon when analyzing
ur results. Patients with a “bumpy” initial postoperative
ourse seemed to deteriorate very rapidly (7 of 9 deaths
ccurred 12 days postoperatively). However, patients
ithout initial complications did well, recovered quickly,
w
p
s
f
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Volume 56, Number 1 Guillou et al 71and went home, usually 8 to 10 days after surgery, without
the need for postoperative rehabilitation or assistance.
Most patients who had uneventful postoperative courses
also remained well in the medium-term, and the follow-up
deaths that have occurred were largely related to the pro-
Fig 3. Kaplan-Meier curve demonstrates actuarial surviv
cular repair.
Fig 4. Kaplan-Meier curve demonstrates actuarial freed
rysm (TAAA) endovascular repair.gression of preoperative nonaneurysmal morbidity. This is aell illustrated by the survival curve (Fig 3), which shows a
ostoperative decline, followed by a plateau during the
ubsequent 24 months.
Because three patients have required emergency ilio-
emoral reinterventions for access vessel complications, we
er thoracoabdominal aortic aneurysm (TAAA) endovas-
om reintervention after thoracoabdominal aortic aneu-al aftom frre more circumspect regarding access site management.
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access, and iliac conduits through a retroperitoneal ap-
proach are liberally used as staged procedures. Also, in
tortuous vessels or angulated aortas, the graft tends to
rotate in the sheath when advanced to its final destination.
This forces the surgeon to manipulate the device within the
aorta to obtain precise positioning of fenestrations or
branches. Increased manipulation within the diseased aorta
can lead to severe cholesterol emboli, something we ob-
served in three patients.
The relatively greater risk of in-hospital death with
advancing age and chronic renal failure underlines the
importance of excluding patients with a poor physiologic
status and limited life expectancy. Table IV demonstrates
the risk of these procedures in elderly patients with renal,
pulmonary, or cardiac comorbidities. By contrast, the en-
couraging midterm results suggest that this technique may
have a role in the (relatively) unfit patient and could also
prove a reasonable alternative to open surgery in fitter
patients.
Previously reported SCI rates ranged from 0% to 30%
after TAAA endovascular repair.5,6,11,14-16 We intensively
monitor the MAP and intervene as necessary to maintain
values 90 mm Hg. We also intervene to maintain a urine
output of60 mL/h and a central venous pressure of15
mm Hg. Although there is no statistically significant sepa-
ration in the SCI rates when comparing our EC and LC
patients, we believe that this is a type II statistical error.
There is a trend toward a lower complication rate with
increasing experience (15% in EC vs 3% in LC groups,
respectively; P .09).We think that this is explained by our
more targeted preoperative and postoperative management
of vital signs. We believe the first 48 postoperative hours are
critical, and any hemodynamic failure during that time is
responsible for SCI or multiple organ failure, or both.
Hemorrhage, decreased urine output, tachycardia, low
MAP, and anemia are all urgently corrected. The reduced
procedure time in the later patients is also likely to be
responsible for the improved results. High postoperative
MAP, measured in the first 24 hours in intensive care, was
an independent predictor of survival.
There is also a significant link between COPD and the
risk of SCI (odds ratio, 8.5; P  .044). This might be
explained by the role of COPD in the increase of central
venous pressure and the influence of the central venous
pressure on CSF pressure, diminishing the perfusion pres-
sure. In the treatment of types I and II TAAAs with
proximal aortic sealing zones that compromise the left
subclavian artery origin, we routinely debranch and revas-
cularize the left subclavian artery as a staged procedure.
This is to preserve arm and (more importantly) vertebral
perfusion, as recommended by the American Society for
Vascular Surgery in TEVAR.17
Endovascular TAAA repairs can be prolonged proce-
dures with significant periods of lower limb exclusion from
the circulation. To reduce the risk of ischemia-reperfusion
syndrome (and its hemodynamic and coagulation conse-
quences), we now routinely restore the lower limb as soons possible. This may also have implications in the preven-
ion of SCI by early perfusion of the internal iliac circula-
ion. Once the main body is inserted and fenestrations are
tented, the distal extension of the graft is deployed and all
nstrumentation is removed from the femoral access to
apidly restore flow to the pelvis and the lower extremities.
he procedure then proceeds from the axillary approach.
ONCLUSIONS
Endovascular treatment of TAAA is evolving rapidly
nd has now reached a degree of maturity in high-volume
ortic and endovascular centers. The aortic anatomy is still
limiting factor, but the progress in imaging and device
onception has begun to overcome this challenge. The
ublished (and unpublished) morbidity and mortality rates
fter open TAAA repair remain significant disincentives to the
se of these very large open operations in most of our fragile
lderly patients. Although short-term and intermediate-term
esults seem encouraging in reports of high-risk patients (as
onfirmed in the present study and shown in others pre-
iously published), long-term results are awaited, espe-
ially in regard to the patency of target vessels. In addi-
ion, we hope that clinical and basic research will yield
reoperative predictors of the consequences of extensive
ortic coverage.
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